^
Association details:
| Biomarker: | PCDHB15 overexpression |
|---|---|
| Cancer: | T Acute Lymphoblastic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A TARGETED DRUG SCREEN REVEALS POTENT INHIBITORS OF T-PLL PRIMARY PATIENT CELLS
Published date:
05/14/2020
Excerpt:
RNA sequencing analyses revealed that higher expression of protocadherin beta 15 (PCDHB15), a plasma membrane protein functioning in cell adhesion, is linked to the sensitivity to ruxolitinib treatment ex vivo.
